Jacc: Cardiooncology最新文献

{"title":"Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib","authors":"Yasuhisa Tatebe PhD,&nbsp;Yuta Tanaka PhD,&nbsp;Yohei Manabe BPharm,&nbsp;Shinobu Okano BPharm,&nbsp;Tsukasa Higashionna MS,&nbsp;Hirofumi Hamano PhD,&nbsp;Kiminaka Murakawa PhD,&nbsp;Yoshito Zamami PhD","doi":"10.1016/j.jaccao.2025.06.011","DOIUrl":"10.1016/j.jaccao.2025.06.011","url":null,"abstract":"<div><h3>Background</h3><div>Osimertinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat patients with epidermal growth factor receptor–mutant non–small-cell lung cancer. Although osimertinib has been linked to heart failure (HF), detailed risk estimates remain unclear.</div></div><div><h3>Objectives</h3><div>The aim of this study was to examine the association between osimertinib use and HF hospitalization.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study using a large-scale Japanese claims database, patients diagnosed with lung cancer between April 2008 and December 2021 who received cancer therapy were identified. Patients were categorized into osimertinib and control groups according to treatment received. The incidence of HF hospitalization during the treatment period was compared between the groups. Multivariable analyses were performed before and after propensity score matching.</div></div><div><h3>Results</h3><div>The osimertinib and control groups included 11,391 and 108,144 patients, respectively. Among the entire cohort, the median age was 70 years (Q1-Q3: 64-76 years), and the median follow-up duration was 173 days (Q1-Q3: 73-448 days). The incidence of HF hospitalization was 9.9 and 4.1 cases per 1,000 person-years in the osimertinib and control groups, respectively. In multivariable analysis, osimertinib was associated with a higher risk for HF hospitalization than control therapy (subdistribution HR: 2.56; 95% CI: 2.07-3.18; <em>P</em> &lt; 0.001). This association remained significant after propensity score matching (subdistribution HR: 2.29; 95% CI: 1.62-3.24; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Osimertinib use was associated with an increased risk for HF hospitalization. Cardiac function should be closely monitored in patients receiving osimertinib.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 6","pages":"Pages 738-748"},"PeriodicalIF":12.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition, But Not Depletion, of Erk Signaling Ameliorates Anthracycline-Induced Cardiotoxicity in Zebrafish.","authors":"Maryam Moossavi, Ping Zhu, Yonghe Ding, David Mondaca-Ruff, Feixiang Yan, Xueling Ma, Xiaolei Xu","doi":"10.1016/j.jaccao.2025.08.005","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.08.005","url":null,"abstract":"<p><strong>Background: </strong>Anthracycline-induced cardiotoxicity (AIC) is a unique type of cardiomyopathy that limits the clinical use of anthracyclines in cancer therapy. Although several cardiomyopathy-related pathways have been identified, including extracellular signal-regulated kinase (ERK) signaling, pathway-specific interventions for AIC remain unclear.</p><p><strong>Objectives: </strong>The aim of this study was to investigate the role of Erk signaling in AIC using zebrafish genetics.</p><p><strong>Methods: </strong>A zebrafish model of AIC was used to screen genes in known cardiomyopathy pathways, including Erk signaling. Heterozygous and homozygous mutants were evaluated for their modifying effects on AIC. In parallel, pharmacologic studies with ERK inhibitors were conducted to assess dose-dependent therapeutic effects of Erk inhibition.</p><p><strong>Results: </strong>mek1^+/- and erk1^+/- mutants conferred protective effects in adult zebrafish with AIC. Consistent with this, Erk phosphorylation was aberrantly elevated in AIC hearts. Although heterozygous mutants mitigated AIC phenotypes, homozygous erk1^-/- mutants caused cardiac dysfunction and worsened AIC. Similarly, pharmacologic inhibition of Erk with temuterkib was therapeutic at low doses but induced dose-dependent cardiotoxicity. Mechanistically, the AIC model exhibited accelerated cardiac senescence, which can be attenuated by Erk inhibition.</p><p><strong>Conclusions: </strong>Aberrant Erk activation contributes to AIC, and controlled Erk inhibition may offer therapeutic benefit, potentially via antiaging mechanisms. However, optimization is essential, as excessive inhibition can be cardiotoxic.</p>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma: JACC: CardioOncology State-of the-Art Review.","authors":"Hari S Raman, Joshua Mitchell, Anju Nohria, Jenica N Upshaw, Ann S LaCasce","doi":"10.1016/j.jaccao.2025.07.011","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.07.011","url":null,"abstract":"<p><p>Classic Hodgkin lymphoma is a highly curable lymphoma that affects primarily younger patients. The therapeutic landscape has evolved and generally consists of varying combinations of chemotherapy and immunotherapy as well as radiation in selected cases. Although most patients are cured of their lymphoma, there is a risk for late treatment-related cardiotoxicity that affects long-term survival and quality of life in this population. Careful consideration of baseline cardiac function and risk factors should be undertaken prior to proceeding with anthracycline-based therapies or thoracic radiation, as adjuvant cardiac-focused efforts may serve to mitigate the risk for cardiovascular dysfunction in this population. This review outlines the evidence supporting current recommendations for assessing baseline cardiotoxicity risk, implementing risk reduction strategies and treatment modifications, the role of multidisciplinary evaluation in high-risk patients, and strategies for long-term cardiac monitoring to minimize treatment-related cardiac morbidity and mortality.</p>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Immune Checkpoint Inhibitor Myocarditis: Can We Do Better?","authors":"Edward Doris, Charlotte Manisty, Sivatharshini Ramalingam, Gary J R Cook, Alexander R Lyon, Muhummad Sohaib Nazir","doi":"10.1016/j.jaccao.2025.08.001","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.08.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional Interaction in Cardio-Oncology Toward Novel Therapeutic Strategies for Cardiovascular Diseases","authors":"Lama Awwad MSc,&nbsp;Laris Achlaug MSc,&nbsp;Sharon Aviram PhD,&nbsp;Ami Aronheim PhD","doi":"10.1016/j.jaccao.2025.04.007","DOIUrl":"10.1016/j.jaccao.2025.04.007","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 554-558"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering the Oncologic Implications of Antihypertensive Therapy","authors":"Ioannis Skalidis MD, PhD,&nbsp;Henri Lu MD,&nbsp;Niccolo Maurizi MD,&nbsp;Georgios Tzimas MD,&nbsp;Panagiotis Antiochos MD","doi":"10.1016/j.jaccao.2025.05.015","DOIUrl":"10.1016/j.jaccao.2025.05.015","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Page 644"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Risk, Health Metrics, and Cancer Prediction","authors":"Gretell Henriquez-Santos MD ,&nbsp;Ji-Eun Kim PhD ,&nbsp;Sant J. Kumar MD ,&nbsp;Alicia A. Livinski MPH, MA ,&nbsp;Jacqueline B. Vo PhD, RN, MPH ,&nbsp;Fang Zhu PhD, MPH ,&nbsp;Jungnam Joo PhD ,&nbsp;Joseph J. Shearer PhD, MPH ,&nbsp;Maryam Hashemian MD, PhD ,&nbsp;Véronique L. Roger MD, MPH","doi":"10.1016/j.jaccao.2025.05.011","DOIUrl":"10.1016/j.jaccao.2025.05.011","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) and cancer are leading global causes of morbidity and mortality. Given the shared risk factors, it is plausible that CVD risk scores and cardiovascular health (CVH) metrics could predict cancer risk.</div></div><div><h3>Objectives</h3><div>The authors sought to identify and summarize studies examining the association between CVD risk scores, CVH metrics, and incident cancer.</div></div><div><h3>Methods</h3><div>A systematic search of 4 databases (Embase, PubMed, Scopus, Web of Science: Core) was conducted in April 2024 without language or date restrictions. Five reviewers (G.H., J.K., S.J.K., M.H., V.L.R.) independently screened records using Covidence software and extracted data from eligible prospective studies (adults aged ≥18 years; cancer incidence as outcome; CVD risk scores or CVH metrics as exposure).</div></div><div><h3>Results</h3><div>Of 4,165 records screened, 13 studies (14 CVD or CVH metrics) were included. Heterogeneity between scales precluded a meta-analysis. Four studies evaluated CVD risk scores (eg, atherosclerotic CVD) and 10 reported CVH metrics (eg, the American Heart Association’s Life’s Simple 7). Sample sizes ranged from 1,880 to 342,226, with median follow-up from 8.1 to 29.6 years. The majority included all types of cancer (71.4%), including breast, lung, colorectal, and prostate cancer types, with cancer events ranging from 387 to 11,643. Higher CVD risk scores were consistently associated with increased cancer risk incidence (HRs: 1.16-3.71). Ideal CVH metrics were associated with reduced risk (HRs: 0.49-0.95).</div></div><div><h3>Conclusions</h3><div>Despite heterogeneity in CVD risk metrics and cancer types, most studies suggested that worse CVD risk scores or CVH metrics predict greater cancer risk. Future studies should focus on specific CVD risk metrics and cancer types to produce evidence suitable for a meta-analysis.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 593-606"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Insights in Bidirectional Cardio-Oncology: Heart Failure Driving Cancer","authors":"Rudolf A. de Boer MD, PhD ,&nbsp;Laura I. Yousif MSc ,&nbsp;Joseph Pierre Aboumsallem PhD,&nbsp;Wouter C. Meijers MD, PhD","doi":"10.1016/j.jaccao.2025.05.014","DOIUrl":"10.1016/j.jaccao.2025.05.014","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 518-522"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ischemic Injury Drives Nascent Tumor Growth Via Accelerated Hematopoietic Aging","authors":"Alexandra A.C. Newman PhD ,&nbsp;José Gabriel Barcia Durán PhD ,&nbsp;Richard Von Itter MPhil ,&nbsp;Jessie M. Dalman BA ,&nbsp;Brian Lim MD ,&nbsp;Morgane Gourvest PhD ,&nbsp;Tarik Zahr PhD ,&nbsp;Kristin M. Wang MPhil ,&nbsp;Tracy Zhang MS ,&nbsp;Noah Albarracin BS ,&nbsp;Whitney G. Rubin BS ,&nbsp;Fazli K. Bozal PhD ,&nbsp;Kory J. Lavine MD, PhD ,&nbsp;Chiara Giannarelli MD, PhD ,&nbsp;Michael Gildea PhD ,&nbsp;Coen van Solingen PhD ,&nbsp;Kathryn J. Moore PhD","doi":"10.1016/j.jaccao.2025.06.005","DOIUrl":"10.1016/j.jaccao.2025.06.005","url":null,"abstract":"<div><h3>Background</h3><div>Patients with peripheral artery disease have an increased risk of cancer development. Aging-associated changes in hematopoietic stem and progenitor cells (HSPCs), including inflammation and increased myelopoiesis, are implicated in both cardiovascular disease and cancer, but their contributions to cardiovascular disease–driven tumor progression are unclear.</div></div><div><h3>Objectives</h3><div>This study sought to study tumor growth after peripheral ischemia and consequent changes within the HSPC bone marrow compartment to uncover mechanisms through which altered hematopoiesis promotes cancer.</div></div><div><h3>Methods</h3><div>Mammary cancer (E0771) growth was monitored in C57BL/6J mice after hind limb ischemia (HLI) or sham surgery. The tumor immune microenvironment, circulatory immune cells, and HSPC compartment were assessed by flow cytometry. Next-generation single-cell RNA and assay for transposase-accessible chromatin sequencing of bone marrow progenitors was performed to assess the distinct and synergistic transcriptomic and epigenetic changes of cancer and peripheral ischemia. The functional impact on tumor progression and persistence of ischemia-induced epigenetic reprogramming of HSPCs and their myeloid progeny was examined by bone marrow transplantation.</div></div><div><h3>Results</h3><div>Peripheral ischemia increased monocyte and neutrophil output at the expense of lymphocytes, driven by a shift toward CD150^hi myeloid-biased hematopoietic stem cells. This was associated with accelerated cancer growth and enrichment of tumors with myeloid cells (monocytes, macrophages, neutrophils) and regulatory T cells. Increased myelopoiesis was also supported by sequencing analyses showing HLI and tumor-induced transcriptional and epigenetic enrichment for inflammatory (NLRP3 inflammasome) and aging-associated neogenin-1, thrombospondin-1) signatures in subsets of monocyte/dendritic progenitors. HLI-accelerated tumor growth and myeloid-skewing was transmissible via bone marrow transplantation, indicating long-term reprogramming of innate immune responses.</div></div><div><h3>Conclusions</h3><div>Peripheral ischemia enhances inflammaging of hematopoietic stem cells and long-lasting alterations to antitumoral immunity, accelerating breast tumor growth.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 559-577"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144867403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared Pathways, Shared Predictions","authors":"Ziwen Long MD, PhD ,&nbsp;Wenying Gao MD, MSc ,&nbsp;Xiang Gao MD, PhD","doi":"10.1016/j.jaccao.2025.06.002","DOIUrl":"10.1016/j.jaccao.2025.06.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 607-608"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}